Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial About CytoDyn CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studie ...

文章核心观点 公司宣布评估leronlimab对复发/难治性微卫星稳定结直肠癌患者疗效的临床试验已对首位患者给药，这是公司为患者带来创新治疗方案使命的重要进展 [1][4] 公司进展 - 公司与Syneos Health合作开展的临床试验已在多个临床点进行患者招募，目前已有8个临床点参与且数量还在增加 [1][2] - 试验的首席研究员是来自乔治城大学和MedStar Health Alliance的Ben Weinberg博士 [2] 行业情况 - 结直肠癌是全球第三大常见癌症类型和第二大癌症相关死亡原因，每年全球约有190万新病例和超90万死亡病例 [3] - 50岁以下人群结直肠癌发病率至少20年来呈上升趋势，部分资料显示该趋势可追溯到30多年前 [3] 公司展望 - 公司认为II期结直肠癌试验给首位患者给药是重要进展，期待推进研究以了解疗法在实体肿瘤肿瘤学中的潜在影响 [4] - 该研究基于公司先前研究，将进一步评估leronlimab在实体肿瘤肿瘤学中的作用机制，公司认为当前科研评估是确定该机制在各种实体肿瘤中适用性的最快途径 [5] 公司简介 - 公司是临床阶段生物技术公司，专注于leronlimab的开发和商业化，该药物是一种研究性人源化IgG4单克隆抗体，公司已在多个治疗领域对其进行研究 [6] 合作方简介 - Syneos Health是领先的完全整合生物制药解决方案组织，能将独特见解转化为成果，加速客户成功，支持多元、公平和包容的文化 [7]

VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company's poster presented at the European Society for Medical Oncology's ("ESMO") Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. This news release may contain forward-looking statements relating to, among other things, clinical trial results, p ...

Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors ...

This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations ...